dactinomycin has been researched along with vitamin u in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
Depatie, C; Hayakawa, J; Mercola, D; Ohmichi, M | 1 |
2 other study(ies) available for dactinomycin and vitamin u
Article | Year |
---|---|
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.
Topics: Activating Transcription Factor 2; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Cyclic AMP Response Element-Binding Protein; Dactinomycin; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gastrointestinal Agents; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phenotype; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured; Vitamin U | 2003 |